| 摘要 |
The invention relates to the use of Dasatinib in the preparation of a drug for treating a mammal exposed to radiation, in particular abdominopelvic radiation exposure, for preventing, limiting, reducing and/or eliminating the early or late side effects of radiation, such as gastrointestinal syndromes. |
